Year: 2020

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) — GT Gold Corp. (TSX-V:GTT ; OTCQX:GTGDF) (the “Company” or “GT Gold”) is pleased to announce that further to its news release of November 2, 2020, it has today closed the first tranche of its fully subscribed non-brokered private placement financing (the “Financing”). The first tranche closing consists of the sale of 1,112,954 common shares at a price of C$1.25 per share for gross proceeds of C$1.39 million. The purchasers in the first tranche closing were existing shareholder Newmont Corporation and members of the company’s management and board. The hold period on the common shares sold in the first tranche of the Financing expires on March 10, 2021.The Company expects to close on the...

SHANGHAI, China, Nov. 10, 2020 (GLOBE NEWSWIRE) — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that its licensing partner, Calliditas Therapeutics AB (NASDAQ: CALT) (“Calliditas”), reported positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which analyzed the effect of Nefecon® versus placebo in 199 patients with primary IgA nephropathy (IgAN).The trial met its primary objective of demonstrating a statistically significant reduction in urine protein creatinine ratio, or proteinuria, after 9 months of treatment, with significant continued improvement at 12 months. The trial also met the key...

中国，上海, Nov. 10, 2020 (GLOBE NEWSWIRE) — 云顶新耀(HKEX 1952.HK)，是一家专注于创新药研发及商业化的生物制药公司，致力于满足大中华区及其它亚洲市场未被满足的医疗需求，今日公司公布了其合作伙伴Calliditas Therapeutics AB(“Calliditas”，纳斯达克股票代码：CALT)报告了全球3期临床试验NefIgArd A部分获得良好结果，该试验分析了Nefecon®对比安慰剂治疗199例原发性IgA肾病（IgAN）患者的疗效。该试验达到了其主要目标，结果显示在治疗9个月后，患者的尿蛋白肌酐比率（或蛋白尿）在统计学上显著降低，在治疗12个月后，有了显著的持续性改善。该试验还达到了关键的次要终点——显示治疗9个月后，即与安慰剂相比，患者肾小球滤过率（eGFR）估计值存在统计学上的显著差异。疗效数据也表明，在与进展为终末期肾病（ESRD）相关的关键因素上具有显著且有益的效果。此外，结果显示Nefecon的耐受性普遍良好。基于这些临床数据，Calliditas计划在2021年第一季度向美国食品药物管理局（FDA）提交加速审批申请，并随后在2021年上半年向欧洲药品管理局提交有条件审批申请。此外，Calliditas还将继续招募160名患者纳入到该试验的B部分，整个研究共360例受试者。该部分旨在作为确证性临床研究，在未来药品上市后持续完成，以证实Nefecon对肾脏的长期保护作用。2019年6月，云顶新耀与Calliditas签订了独家授权许可协议，授予云顶新耀在中国（包括香港、澳门、台湾地区）和新加坡开发和商业化Nefecon的专属权利。云顶新耀目前正在招募患者，作为其全球3期临床试验的一部分，以支持该药物在中国获批用于IgA肾病患者。云顶新耀内科领域首席医学官朱正缨博士表示：“我们非常高兴看到这组强有力的临床数据结果。我们继续在中国尽快招募IgA肾病患者，以支持开展NeflgArd试验，我们期待日后能在这些数据的基础上获得更好的结果。”云顶新耀首席执行官、医学博士博科瑞表示：“这组令人鼓舞的临床数据再次佐证了Nefecon有潜力成为全球首个获批治疗IgA肾病的新选择。中国约有200万IgA肾病患者，我们致力于推进这项临床试验并努力为中国患者提供这种重要治疗选择。”有关NefeconNefecon是布地奈德的口服靶向释放制剂，其有潜力成为首个用于治疗IgA肾病的药物。Nefecon这种新剂型，可将布地奈德特异性递送至回肠的派尔集合淋巴结处（负责产生分泌性免疫球蛋白A）。云顶新耀的合作伙伴Calliditas...

Board Member Brian Shure will join executive team as Chief Financial OfficerSteve Neil will remain at the Company in a senior capacitySALINAS, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Indus Holdings, Inc. (CSE: INDS; OTCQX: INDXF), a leading, vertically-integrated cannabis company (the “Company”), with capabilities in cultivation, extraction and manufacturing, brand sales, marketing and distribution, is pleased to announce that Brian Shure has been appointed as Chief Financial Officer.In anticipation of upcoming needs, the Company announces that Brian Shure, currently a Board member and Chairman of its Audit Committee, has accepted his appointment as Chief Financial Officer effective today. Steve Neil will remain with the company in a senior capacity and will focus his efforts on preparing the company for a potential US registration...

MONTREAL, Nov. 09, 2020 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (OR: TSX & NYSE) is pleased to announce a fourth quarter 2020 dividend of C$0.05 per common share. The dividend will be paid on January 15, 2021 to shareholders of record as of the close of business on December 31, 2020.For shareholders residing in the United States, the U.S. dollar equivalent will be determined based on the daily rate published by the Bank of Canada on December 31, 2020. This dividend is an “eligible dividend” as defined in the Income Tax Act (Canada).The Company also wishes to remind its shareholders that it has implemented a dividend reinvestment plan (the “Plan”). Shareholders who are residents of Canada and the United States may elect to participate in the Plan in connection with the dividend to...

MONTRÉAL, 09 nov. 2020 (GLOBE NEWSWIRE) — Redevances Aurifères Osisko Ltée (la « Société » ou « Osisko ») (TSX et NYSE : OR) a le plaisir d’annoncer un dividende pour le quatrième trimestre de 2020 de 0,05 $ CAD par action ordinaire. Le dividende sera payé le 15 janvier 2021 aux actionnaires inscrits aux registres en date du 31 décembre 2020 à la fermeture des bureaux.Pour les actionnaires résidant aux États-Unis, le dollar américain équivalent sera déterminé en fonction du taux de change journalier publié par la Banque du Canada le 31 décembre 2020. Ce versement de dividende est considéré comme un dividende déterminé, tel que défini par la Loi de l’impôt sur le revenu (Canada).La Société souhaite aussi rappeler à ses actionnaires inscrits au Canada et aux États-Unis qu’elle a mis en place un régime de réinvestissement des...

MONTRÉAL, 09 nov. 2020 (GLOBE NEWSWIRE) — Redevances Aurifères Osisko Ltée (la « Société » ou « Osisko ») (TSX et NYSE : OR) annonce aujourd’hui ses résultats financiers consolidés pour le troisième trimestre de 2020.Faits saillants (montants indiqués en dollars canadiens, sauf indication contraire)Record des produits provenant des redevances et des flux de 41,2 millions de dollars (T3 2019 – 33,9 millions de dollars);Record des flux de trésorerie générés par les activités d’exploitation de 36,1 millions de dollars (T3 2019 – 28,3 millions de dollars); 31,7 millions de dollars avant la variation des éléments hors caisse (T3 2019 – 25,1 millions de dollars);Marge monétaire1 record de 96,4 % sur les droits de redevances et de flux de métaux, générant 39,7 millions de dollars en flux de trésorerie d’exploitation, en plus d’une marge...

MONTRÉAL, Nov. 09, 2020 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (OR: TSX & NYSE) today announced its consolidated financial results for the third quarter of 2020.Highlights (amounts in Canadian dollars, except otherwise noted)Record revenues from royalties and streams of $41.2 million (Q3 2019 – $33.9 million);Record cash flows from operating activities of $36.1 million (Q3 2019 – $28.3 million); $31.7 million before changes in non-cash working capital items (Q3 2019 – $25.1 million);Record cash operating margin1 of 96.4% from royalty and stream interests, generating $39.7 million in operating cash flow, in addition to a cash operating margin of $0.7 million from offtake interests;Earned 16,739 GEOs2 (Q3 2019 – 18,123 GEOs);Net earnings of $12.5 million, $0.08 per basic share (Q3 2019 – net...

Company delivers strong results despite being adversely affected by California WildfiresVertically-integrated California cannabis leader reports highest revenue quarter since its inceptionSALINAS, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Indus Holdings, Inc. (“Indus” or the “Company”) (CSE:INDS; OTCQX: INDXF), a leading, vertically-integrated, California-focused cannabis company, announces its financial results for the third quarter ended September 30, 2020 following the previously released preliminary financial highlights. All figures stated are in US Dollars.Third Quarter Financial Highlights:Revenue generated for the three-month period ended September 30, 2020, was $14.1 million; a 40% year-over-year growth from the third quarter last year and an increase of 43% from the prior quarter. As a percentage of revenues, owned...

VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) — Hanwei Energy Services Corp. (TSX: HE) (“Hanwei” or the “Company”), today provided an update as to its acquisition of certain additional Entice assets.As previously reported, the Company completed its agreement to acquire out of a receivership proceeding certain oil and gas facilities, wells, and rights adjacent to its Entice Lands on June 30, 2020.The transfer of the assets from the receivership were subject to regulatory approval. The application for such approval has been rejected by the regulator, following the assessment of the Liability Management Rating relating to the oil and gas assets of the Company.The Company’s Entice Lands have been shut in as an adjacent gas handling plant accommodating gas production from these wells remains closed. The acquisition of the...